Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Top Cited Papers
Open Access
- 1 January 2016
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 6 (2) , 262-271
Abstract
Purpose: Positron Emission Tomography (PET) imaging of HER2 expression could potentially be used to select patients for HER2-targed therapy, predict response based on uptake and be used for monitoring. In this phase I/II study the HER2-binding Affibody molecule ABY-025 was labeled with 68Ga-gallium ([68Ga]ABY-025) for PET to study effect of peptide mass, test-retest variability and correlation of quantified uptake in tumors to histopathology.Keywords
This publication has 30 references indexed in Scilit:
- Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local eventsEuropean Journal of Cancer, 2014
- The ErbB/HER family of protein-tyrosine kinases and cancerPharmacological Research, 2014
- Imaging EGFR and HER2 by PET and SPECT: A ReviewMedicinal Research Reviews, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2012
- HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysisBreast Cancer Research and Treatment, 2011
- Structural basis for high-affinity HER2 receptor binding by an engineered proteinProceedings of the National Academy of Sciences, 2010
- HER2 status in a population-derived breast cancer cohort: discordances during tumor progressionBreast Cancer Research and Treatment, 2010
- Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody MoleculesJournal of Nuclear Medicine, 2010
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999